Dr. Martens (LON:DOCS) Shares Down 11.6% – Here’s Why

Dr. Martens plc (LON:DOCS)’s share price dropped 11.6% during mid-day trading on Tuesday . The stock traded as low as GBX 65 and last traded at GBX 66.90. Approximately 9,032,986 shares were traded during trading, an increase of 342% from the average daily volume of 2,043,681 shares. The stock had previously closed at GBX 75.65.

Dr. Martens News Roundup

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Berenberg Bank reaffirmed a “buy” rating on DOCS, which supports investor confidence in the brand and long-term growth potential. Broker Rating
• Negative Sentiment: Dr. Martens projected flat revenue for 2026 while saying it will scale back discounts — a move that should help margins but signals limited top-line growth near term, which is weighing on the share price. Revenue Guidance Article

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a report on Tuesday. Peel Hunt reissued a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Price Performance

The company has a market cap of £646.63 million, a price-to-earnings ratio of 39.35, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The company has a fifty day simple moving average of GBX 76.21 and a two-hundred day simple moving average of GBX 83.39. The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27.

Dr. Martens (LON:DOCS) last issued its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, equities research analysts anticipate that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Robert Hanson bought 96,000 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The stock was purchased at an average price of GBX 79 per share, with a total value of £75,840. In the last three months, insiders bought 97,130 shares of company stock worth $7,673,816. Company insiders own 2.79% of the company’s stock.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.